Putative preneoplastic foci in the human prostate.
Our knowledge of prostate cancer is less well-defined than our knowledge of cancers of other organs. In the colon, for example, morphological criteria to identify carcinomas in situ and some putative preneoplastic lesions are clear; phenotypic differences in the expression of enzymes and antigens are documented in experimental models and are starting to be defined in humans. Experimental models of cancer of the liver and colon show evidence that "enzyme-altered foci" are preneoplastic. In these organs, the "normal" context is much clearer than in the prostate. In contrast, in the prostates of men in the same age range as those who develop prostate cancer, morphological aberrations are almost always present, diverse, and poorly understood. Murphy and Gaeta said that, "in the study of prostatic disease..., almost every aspect remains controversial...[and].... many of the 'known facts' concerning prostatic disease are poorly documented..." While being aware that the definitions of all benign and malignant lesions of the prostate are based on complex morphological criteria which must form the contemporary context for comparisons, our laboratory is searching for markers that will permit the identification of putative preneoplastic lesions in the prostate. In our opinion, these changes will not be found most efficiently, if they are present at all, in long established cell lines, advanced carcinomas, or serially transplantable xenografts of primary prostatic carcinomas. Our preliminary data suggest that several enzyme histochemical and immunohistochemical approaches are worthy of study. Markers that show promise include acid phosphatase, 5'-nucleotidase, leucine aminopeptidase, and CD44.(ABSTRACT TRUNCATED AT 250 WORDS)
Pretlow
T G
TG
Institute of Pathology, Case Western Reserve University Medical Center, Cleveland, OH 44106.
Nagabhushan
M
M
Sy
M
M
Guo
Y
Y
Pretlow
T P
TP
D015720:5'-Nucleotidase / Q000032:analysis; D000135:Acid Phosphatase / Q000032:analysis; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D002278:Carcinoma in Situ / Q000473:pathology*; D002352:Carrier Proteins / Q000032:analysis; D006801:Humans; D018960:Hyaluronan Receptors; D007931:Leucyl Aminopeptidase / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D011230:Precancerous Conditions / Q000473:pathology*; D011467:Prostate / Q000033:anatomy & histology / Q000254:growth & development / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000473:pathology*; D011956:Receptors, Cell Surface / Q000032:analysis; D016201:Receptors, Lymphocyte Homing / Q000032:analysis
D015703:Antigens, CD; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D018960:Hyaluronan Receptors; D011956:Receptors, Cell Surface; D016201:Receptors, Lymphocyte Homing; D000135:Acid Phosphatase; D015720:5'-Nucleotidase; D007931:Leucyl Aminopeptidase